ProCE Banner Activity

CME

CCO Independent Conference Highlights of the 2023 ASCO Genitourinary Cancers Symposium

Conference Coverage
Text Module

Review expert perspectives on the most clinically relevant data on prostate, bladder, and renal cancers presented at ASCO GU 2023.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 28, 2023

Expiration: April 27, 2024

No longer available for credit.

Share

Faculty

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Yale Cancer Center
New Haven, Connecticut

Elizabeth R. Plimack

Elizabeth R. Plimack, MD, MS, FASCO

Deputy Director
Professor of Medical Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Gilead Sciences, Inc., and Pfizer Inc.

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.

Target Audience

This program is intended for global physicians and other healthcare professionals who care for patients with genitourinary cancers.

Program Learning Goal

The goal of this activity is to improve the understanding of healthcare professionals globally on recent practice changing clinical data on the treatment of patients with genitourinary cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with early-stage and metastatic genitourinary cancers

  • Identify subpopulations of patients with genitourinary cancers most likely to benefit from a specific treatment plan based on prognostic or predictive markers

  • Evaluate new data on novel agents and therapeutic approaches for patients with genitourinary cancers

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Yale Cancer Center
New Haven, Connecticut

Daniel P. Petrylak, MD: consultant/advisor/speaker: Ada Cap (Advanced Accelerator Applications) Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Exelixis, Gilead Sciences, Incyte, Infinity Pharmaceuticals, Ipsen, Janssen, Lilly, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seattle Genetics, Urogen; researcher: Ada Cap (Advanced Accelerator Applications), Agensys Inc, Arvinas, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol-Myers Squibb, Clovis Oncology, Eisai, Endocyte, Genentech, Gilead Sciences, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, Seattle Genetics.

Elizabeth R. Plimack, MD, MS, FASCO

Deputy Director
Professor of Medical Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS: consultant/advisor/speaker: Astellas, AstraZeneca, Aveo, Bristol-Myers Squibb, Calithera, EMD Serono, Exelixis, IMV, Infinity Pharma, Janssen, MEI, Merck, Natera, Pfizer, Regeneron, Seattle Genetics; researcher (paid to institution): Astellas, Bristol-Myers Squibb, Genentech, Merck.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 28, 2023, through April 27, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.